efoodSafety.Com Inc. Reports That the Bird Flu Has Spread From Human to Human
Posted on: Thursday, 13 July 2006, 12:00 CDT
Patricia Ross-Gruden, president and CEO of eFoodSafety.com Inc. (OTCBB: EFSF), announced today that eFoodSafety.com Inc. confirms reports that the bird flu virus has spread from human to human.
A report from Indonesia stated that a woman contracted the H5N1 virus, spread it to her 10-year-old son, and five other blood relatives. All but one who contracted the virus had died.
On Nov. 7, 2005, Lee Jong-Wook, leader of the World Health Organization (WHO), stated, "It is only a matter of time before an avian-flu virus -- most likely H5N1 -- acquires the ability to be transmitted from human to human, sparking the outbreak of human pandemic influenza. We don't know when this will happen. But we do know that it will happen."
The recent findings in Indonesia provide proof that the bird flu virus has now inevitably begun to spread between humans.
In the June 24, 2006, edition of the Washington Times, United Nations Bird Flu Chief David Nabarro said this is a "vivid reminder of the need to keep a very close watch on what the virus is doing." A pandemic of bird flu would be an unprecedented disaster. Economically, the World Bank warned that a bird flu pandemic could cause global gross domestic product to drop by 2 percent -- or about $800 billion a year. It is difficult to estimate a reasonable death count, but WHO forecasts have consistently remained at 2 million to 7.4 million deaths worldwide."
Ongoing testing of eFoodSafety.com Inc.'s bird flu formulation -- Citroxin -- is currently under way in this Far Eastern region. Gruden commented, "We specifically began testing in Thailand to be as close as possible to the 'hot spot' where this potential pandemic could break out."
About eFoodSafety.com Inc.
eFoodSafety.com Inc. is dedicated to improving health conditions around the world through its innovative technologies. The company's Knock-Out Technologies Ltd. subsidiary has developed an environmentally safe sporicidal product formulated entirely of food-grade components that eradicates anthrax and a germicidal product, Big 6 Plus - EPA Reg. No. 82723-1, that kills six major bacteria: E-coli, Listeria, Pseudomonas, Salmonella, Staphylococcus, and Streptococcus, Avian Influenza, and Black Mold. The sporicidal product has completed its final efficacy laboratory study requisite for EPA registration. In the study, it eradicated both Clostridium Sporogenes and Bacillus Subtilis with 100% efficacy on both hard and porous surfaces. The company's MedElite Inc. subsidiary distributes clinically proven products to physicians who then prescribe the products for their patients. It is the exclusive U.S. and worldwide distributor of the Talsyn(TM)-CI/bid Scar Cream that has been clinically proven to facilitate and improve the appearance, redness and strength of scars (www.talsyn.com). The company is also is a distributor for Cinnergen(TM), a nonprescription liquid whole food nutritional supplement that promotes healthy glucose metabolism (www.cinnergen.com), and Trimmendous(TM), a weight loss formula focusing on the body's 24-hour metabolic processes. The company has recently entered into a joint venture agreement with CK41 Direct Inc. to launch an anti-acne skin care system, with a branded name and celebrity spokesperson to be announced in the near future.
Please visit the company's Web site at: http://www.efoodsafety.com.
Safe Harbor Forward-Looking Statements
Statements contained in this release that are not strictly historical are "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933 as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements are made based on information available as of the date hereof, and the company assumes no obligation to update such forward-looking statements. Editors and investors are cautioned that such forward-looking statements involve risks and uncertainties and the company's actual results may differ from these forward-looking statements. Such risks and uncertainties include but are not limited to demand for the company's products and services, our ability to continue to develop markets, general economic conditions, our ability to secure additional financing for the company and other factors that may be more fully described in reports to shareholders and periodic filings with the Securities and Exchange Commission.
Source: Business Wire
Related Articles
- INVEGA(R) Receives Positive Opinion From European Committee for Human Medicinal Products for Treatment of Schizophrenia
- Vaccines Protect Birds from Bird Flu, other Viruses
- USDA Readies Own Human Pandemic Plan for Bird Flu
- WHO Experts Discuss Plan for Curbing Potential Human Pandemic
- Human Bird Flu Vaccine Can Meet Demands of Large Quantity Production: Expert
- Inverness says rapid flu test may not work on humans
- Rapid Flu Test May Not Work on Humans
- Madrid Runs Out of Flu Vaccine Due to Bird Flu Panic
- Next human pandemic "inevitable," says U.S. scientist
- Bird flu vaccine may be too late for pandemic: expert
User Comments (0)

RSS Feeds